It is the job of the press to cover power, not cover for power—to hold those in power accountable by documenting what's happening on the ground and amplifying voices at the grassroots. In this critical moment, as attacks on the media escalate, we must continue to cover crackdowns on dissent, immigrants, the LGBTQ+ community, public health and academic freedom. If our journalism is important to you, please donate today. Every dollar makes a difference. Thank you so much.
Democracy Now!
Amy Goodman
It is the job of the press to cover power, not cover for power—to hold those in power accountable by documenting what's happening on the ground and amplifying voices at the grassroots. In this critical moment, as attacks on the media escalate, we must continue to cover crackdowns on dissent, immigrants, the LGBTQ+ community, public health and academic freedom. If our journalism is important to you, please donate today. Every dollar makes a difference. Thank you so much.
Democracy Now!
Amy Goodman
We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.
Please do your part today.
StoryMay 13, 2025
StoryMay 13, 2025
StoryMay 13, 2025
StoryMay 13, 2025
Web ExclusiveMay 13, 2025
Web ExclusiveMay 09, 2025
Web ExclusiveApr 21, 2025
Web ExclusiveApr 17, 2025
The U.S. Food and Drug Administration has approved a drug to slow the cognitive decline of patients with mild dementia and other symptoms of early Alzheimer’s disease. Approval of the intravenously administered drug Leqembi clears the way for Medicare and other health insurers to begin covering the extremely expensive treatment.
We are hiring a Director of Technology to lead our broadcast, digital and IT operations!
Top